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TRAP1 chaperone protein mutations and
autoinflammation
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We identified a consanguineous kindred, of three affected children
with severe autoinflammation, resulting in the death of one
sibling and allogeneic stem cell transplantation in the other two.
All three were homozygous for MEFV p.S208C mutation; however,
their phenotype was more severe than previously reported,
prompting consideration of an oligogenic autoinflammation model.
Further genetic studies revealed homozygous mutations in TRAP1,
encoding the mitochondrial/ER resident chaperone protein tumour
necrosis factor receptor associated protein 1 (TRAP1). Identification
of a fourth, unrelated patientwith autoinflammation and compound
heterozygous mutation of TRAP1 alone facilitated further functional
studies, confirming the importance of this protein as a chaperone of
misfolded proteins with loss of function, which may contribute to
autoinflammation. Impaired TRAP1 function leads to cellular stress
and elevated levels of serum IL-18. This study emphasizes the
importance of considering digenic or oligogenic models of dis-
ease in particularly severe phenotypes and suggests that auto-
inflammatory disease might be enhanced by bi-allelic mutations
in TRAP1.
DOI 10.26508/lsa.201900376 | Received 12 March 2019 | Revised 19 December
2019 | Accepted 20 December 2019 | Published online 27 December 2019
Introduction
Many cellular functions generate by-products which are tightly
managed to maintain cellular homeostasis. When these homeo-
static pathways are perturbed, cellular stress ensues (Galluzzi et al,
2018). Cellular stress can be physiologically vital for host survival.
For example, immune cellular stress in response to pathogen-related
signals leads to the activation of important immune pathways that are
vital to resolve infection and promote tissue repair. It is now recog-
nized that the innate immune system has evolved to modulate
the negative effects of pathogens on host homeostasis (Soares
et al, 2017). For example, the NLRP3 inflammasome can recognize
damage-associated molecular patterns and other signs of cellular
damage, including reactive oxygen species (ROS), and it responds to
these rapidly by assembling its components to release of IL-1 and
IL-18, important pro-inflammatory cytokines central to many innate
immune responses (van de Veerdonk et al, 2011; Zhou et al, 2011).
Dysregulation of innate immune cellular homeostasis can result
from genetic mutation, causing a growing number of monogenic
autoinflammatory diseases resulting from dysregulation of key
inflammatory pathways (Manthiram et al, 2017). One such pathway
is the unfolded protein response which responds to accumulation
of intracellular misfolded proteins, important in the pathogenesis
of several autoinflammatory diseases (Park et al, 2012). In particular,
patients with tumour necrosis factor receptor associated periodic
syndrome (TRAPS) have a heterozygous mutation of TNFRSF1A
which causes TNFR1 to fold incorrectly, activating the unfolded
protein response pathway in the ER causing increased intracellular
ROS, and dysregulated production of IL-1β and other pro-inflammatory
cytokines resulting in autoinflammation (Simon et al, 2010; Bulua et al,
2011; Dickie et al, 2012). Another example is the buildup of damaged,
oxidised proteins driving the pathogenesis of the proteasome dis-
ability syndromes (Agarwal et al, 2010; Arima et al, 2011; Kitamura et al,
2011; Liu et al, 2011; Kanazawa, 2012). More recently, mutations in TRNT1
encoding a nucleotidyltransferase required for the maturation of
cytosolic andmitochondrial tRNAs, essential for protein synthesis, has
been linked to congenital sideroblastic anemia with immunodefi-
ciency, fevers, and developmental delay (SIFD). Loss of TRNT1 activity
disrupts protein homeostasis leading to mitochondrial damage, ROS
production and autoinflammation (Wiseman et al, 2013; Chakraborty
et al, 2014; Giannelou et al, 2018).
In this study, we have identified a consanguineous kindred, with
three affected children with a very severe autoinflammatory dis-
ease, resulting in the death of one sibling and need for allogeneic
haematopoietic stem cell transplantation (allo-HSCT) in the two
surviving siblings. They harboured the recently described pathogenic
homozygous p.S208C mutation in MEFV. This gene is mutated in pa-
tients with familial Mediterranean fever (FMF) and pyrin-associated
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autoinflammation with neutrophilic dermatosis (PAAND) (Masters
et al, 2016; Moghaddas et al, 2017). We recently reported homozy-
gous MEFV p.S208C and p.S208T mutation as the cause of auto-
inflammation with recurrent fevers, erythematous skin rashes,
peripheral blood eosinophilia, and intestinal inflammation (Hong,
2018). However, the phenotype in the kindred studied herein was
much more severe than that associated with our previous report of
autoinflammation caused by homozygous MEFV p.S208 mutation.
Therefore, further genetic studies were undertaken, ultimately
revealing a homozygous variant in a gene in the same genomic
region, TRAP1, which encodes the mitochondrial chaperone protein
tumour necrosis factor receptor associated protein 1 (TRAP1).
Identification of a fourth, unrelated patient with autoinflammation
in association with compound heterozygous variants in TRAP1
(without mutation in any other known autoinflammatory genes)
suggested that mutant TRAP1 may contribute to autoinflammation,
via increased ROS generation. These findings emphasize the im-
portance of considering digenic or oligogenic models of disease in
patients with particularly severe autoinflammatory phenotypes.
Results and Discussion
Three siblings from a consanguineous (first-cousin) Pakistani family
presented with a severe autoinflammatory phenotype. The index case
(IV-1, Fig 1A–D) first presented at 2 wk of age with severe oral and lip
ulceration, nasal inflammation (Fig 1A–C), recurrent fevers without
obvious periodicity or evidence of infection every 4–6 wk and lasting
several days, nasal septal collapse due to chronic inflammation (Fig
1A), a transientmaculopapular rash (Fig 1D), and failure to thrive. There
was an intense and continuous acute phase response, with persis-
tently elevated serum amyloid A protein (SAA) and C reactive protein
(CRP) concentrations usually exceeding 100mg/l (reference range < 10
for both; Fig 1I). Levels of serum IgD persistently exceeded the upper
limit of detection of 900 IU/ml for the assay (reference range < 100).
The patient did not have mevalonic aciduria, and routinely available
genetic screening for the common causes of autoinflammatory dis-
ease revealedwild-type forMVK, TNFRSF1A, NLRP3, andMEFV (exons 10
and part of exon 2, which at the time was offered in routine clinical
care). Further details of all the immunological and histological in-
vestigations undertaken are provided in Table S1. The original best fit
clinical description made more than 20 yr ago was that of “congenital
Wegener’s granulomatosis” (Hoffman et al, 1992), although anti-
neutrophil cytoplasmic antibodies against proteinase 3 or mye-
loperoxidase were repeatedly negative. Various therapies (all at
standard paediatric doses, Table S1) were tried including, non-
steroidal anti-inflammatory drugs, daily prednisolone (0.3 to 2 mg/
kg/d), pulsed intravenous methylprednisolone, colchicine, cyclo-
phosphamide, azathioprine, mycophenolate mofetil, thalidomide,
rituximab and anakinra, all with limited or no success. She received
a single dose of infliximab (a murine-human chimeric monoclonal
antibody against tumour necrosis factor); however, the patient
deteriorated with worsening of rash and fever in the first 3 d after
the infusion; infliximab was subsequently discontinued. Her
symptoms were partially controlled with high-dose daily pred-
nisolone, although there continued to be an intense persistent
acute phase response (Fig 1I). In view of ongoing chronic inflam-
mation with chronically elevated SAA and CRP, corticosteroid de-
pendency, and failure to thrive, she underwent allogeneic HSCT
from a fully matched (10/10) nonrelated donor at the age of 13 yr.
Within 1 mo, there was complete resolution of all her symptoms,
normalisation of her inflammatory markers and IgD levels, and over
time, normalisation of growth. She engrafted fully (100% donor
chimerism) with no major complications and remains well and off
all medication now 12 yr posttransplantation. Her younger female
sibling (IV-2) also had similar symptoms, persistently elevated
acute-phase reactants (Fig 1I), and high serum IgD (Table S1). Her
symptoms and serological markers were initially partially con-
trolled by anakinra 2–3 mg/kg/d; this clinical and serological re-
sponse was short-lived, however (Fig 1I). Thus, she also underwent
allogeneic HSCT from a fully matched nonrelated donor, which also
cured her illness and she remains well and off all medication now
10 yr posttransplantation. A third sister (IV-4) presented at 2 mo of
age with a severe clinical phenotype similar to the index case but
with the addition of multifocal sterile osteomyelitis with lytic bony
lesions and neutrophil infiltration on bone biopsy (Fig 1E–G and
Table S1), including the cervical spine that required surgical sta-
bilisation. This infant died at age 12 mo from acute cervical mye-
lopathy from cervical vertebral collapse. The parents and two
unaffected siblings were also formally assessed for the possibility
of autoinflammation. Detailed past medical history and examina-
tion did not indicate any clinical phenotype. In addition, wemeasured
SAA and CRP in the parents and both unaffected siblings and did not
find any indication of subclinical inflammation. Further details of
investigations and therapies received by all three patients are
provided in Table S1.
Homozygosity mapping and parametric multipoint linkage analysis
of the three affected children, two unaffected siblings, and both
parents in this pedigree identified a single 5-Mb region on chromo-
some 16 that segregated with the disease within the family. Targeted
resequencing of this region identified 118 coding change variants in 53
genes. Because of the unusual clinical presentation, we eliminated
variants present with a frequency of more than 0.01 in the 1,000
genomes database (http://www.1000genomes.org), the Exome Vari-
ant Server (ESP) (https://evs.gs.washington.edu/EVS), the Exome
Aggregation Consortium database (now aggregated into GnomAD),
the Genome Aggregation Database (GnomAD) database (https://
gnomad.broadinstitute.org/), and the Greater Middle East data-
base (http://igm.ucsd.edu/gme/). After screening 100 healthy
controls from the same Pakistani tribe (exact tribe withheld to
maintain confidentiality), with further elimination of unlikely
candidates, and further screening of the extended kindred (Fig 1H),
two variants of interest remained. The first was a nonsynonymous
homozygous variant in a previously unscreened region of exon 2 of
MEFV c.622A>T, causing a p.S208C amino acid substitution. This
variant was of considerable interest because mutations inMEFV are
associated with the autoinflammatory diseases, FMF and PAAND
(Masters et al, 2016; Moghaddas et al, 2017). We recently reported
that homozygous MEFV substitution of serine 208 with threonine or
cysteine causes an autoinflammatory disease associated with re-
current fevers, skin rashes, intestinal inflammation, and peripheral
blood eosinophilia (Hong, 2018). This MEFV amino acid residue is
part of the 14.3.3 binding motif; mutation in another key residue of
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this motif (S242) is associated with the dominant autoinflammatory
disease PAAND (Masters et al, 2016; Moghaddas et al, 2017). The
particularly severe phenotype of the kindred studied herein
prompted consideration of other possibly contributory genetic
mutations in a digenic or oligogenic disease model. We identified a
second homozygous variant of interest in close proximity (<0.5 Mb)
to this MEFV variant, a nonsynonymous variant in the gene for the
mitochondrial protein tumour necrosis factor receptor associated
protein 1 (TRAP1) c.383G>A, leading to a p.R128H amino acid change,
classified as damaging by three in silico predictive tools (Polyphen2
[Adzhubei et al, 2010], SIFT [Kumar et al, 2009], and MutationTaster
[Schwarz et al, 2010]). TRAP1 is a member of the heat shock protein
90 family, a collection of chaperone proteins involved in the folding
of nascent and damaged proteins that assist in the stabilisation of
these proteins under cellular stress (Chen et al, 2005). TRAP1 is
involved in managing unfolded proteins in the mitochondria and
the ER (Chien et al, 2011; Matassa et al, 2011; Takemoto et al, 2011).
This function reduces mitochondrial damage and, thus, the pro-
duction of ROS. ROS are important activators of innate immunity,
and elevated levels of mitochondrial ROS (mROS) have been
Figure 1. Clinical phenotype and
response to treatment.
(A) Recurrent nasal inflammation
resulting in cartilaginous nasal septal
collapse and “saddle nose deformity”
in the index case IV-1. (B) chronic
ulceration of the hard palate leading to
scarring (IV-1). Biopsy of mucosal
ulcers revealed neutrophilic infiltration
(see Table S1 for full histological
descriptions). (C) ulcers also affected
the lips causing scarring (IV-1). Note also
the nasogastric feeding tube required for
nutritional support for failure to
thrive. (D) erythematous rash on upper
arm (IV-1). (E, F, G) Sterile multifocal
osteomyelitis in Patient IV-4, resulting
in expansion and lytic inflammation in
the medial end of the left clavicle (E)
(arrowed), and of (F) distal femur
(arrowed), and multiple cervical
vertebra, as depicted in (G) showing a
computer tomography scan of a
cervical vertebra with lytic lesions
(arrowed). Cervical myelopathy from
vertebral collapse was the cause of
death in Patient IV-4. (H) Family
pedigree showing status of TRAP1
mutation and the linked MEFV
pathological variants. (I) Acute phase
reactants plotted against treatments in
IV-1, and IV-2, black line denotes C
reactive protein, red lines serum
amyloid A. WT, wild-type; HSCT,
haematopoietic stem cell
transplantation.
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implicated in the pathogenesis of a number of autoinflammatory
diseases (Tassi et al, 2010; Borghini et al, 2011; Bulua et al, 2011; Carta
et al, 2012; Dickie et al, 2012; Omenetti et al, 2013; Giannelou et al,
2018); thus, impairment of functional TRAP1 protein might exac-
erbate any pre-existing autoinflammatory propensity.
We subsequently included TRAP1 in a targeted next-generation
sequencing panel used for routine diagnostic purposes (Omoyinmi
et al, 2017), and in that context, screened this gene in 315 patients
with suspected autoinflammation. This led to the identification of a
fourth, unrelated patient (patient 4) with variants in this gene. This
was a Caucasian adult female (of adopted parents, hence no bi-
ological family history available) with an autoinflammatory disease
characterised by episodic fevers and systemic inflammation from
early in life, cervical lymphadenopathy, arthralgia, elevated acute-phase
reactants, including high SAA, partial response to corticosteroids, and
complete response to anakinra during these inflammatory exacer-
bations. In total, she had three rare variants in TRAP1, all predicted to
be damaging: these included the same c.383 G>A (p.R128H) variant
(heterozygous) as identified in our kindred and two other heterozy-
gous variants, c.947 G>A (p.R316H), and c.1330T>A (p.Y444N). To confirm
variant segregation, we used TA cloning in this individual (TOPO-TA kit;
Invitrogen) and demonstrated that p.R316H and p.Y444N segregated
together, with p.R128H segregating on the other chromosome. This
patient had no other mutations identified in any other auto-
inflammatory gene (including MEFV) included in our targeted panel
(Omoyinmi et al, 2017). Subsequently, three TRAP1 p.R128H homozy-
gotes have been identified in the Exome Aggregation Consortium
database, and six in the gnomADdatabase. The frequency of this allele
in South Asian populations is 0.01 in the gnomAD database. Pene-
trance of this variant may be incomplete, and we suspect that it may
enhance the inflammatory phenotype in combination with other
mutations such as the MEFV p.S208C mutations or the additional
TRAP1 variants within this study, and may be less severe in isolation.
TRAP1 has a role in both the ER and the mitochondria, in par-
ticular refolding proteins and thus reducing mROS levels, ER stress,
and cellular damage (Matassa et al, 2011). Given the role that ROS is
known to play in inflammation (Zhou et al, 2003, 2011; Naik & Dixit,
2011; Mittal et al, 2014) and specifically in autoinflammation (Kirkali
et al, 2008; Tassi et al, 2010; Bulua et al, 2011; Carta et al, 2012;
Dickie et al, 2012; Omenetti et al, 2013; Giannelou et al, 2018), we
measured the levels of oxidative stress and mROS in PBMCs from
patient 4 and in three healthy age-matched controls using flow
cytometry. PBMCs were not available for these experiments from
any of the children in our pedigree (Fig 1H) because two had already
undergone allogeneic HSCT and the third was deceased. MitoSox
(MS) fluorescence is proportional to superoxide levels in the mi-
tochondria, and H2DCFDA fluorescence measures the accumulation
of peroxylated proteins and overall intracellular oxidative stress.
Compared with healthy controls, mROS were significantly elevated in
the lymphocytes of patient 4 (P < 0.001), but not in monocytes (Fig 2A
and B). Overall intracellular oxidative stress was elevated in both
lymphocytes (P < 0.001) and monocytes (P < 0.001) of patient 4,
compared with healthy controls (Fig 2C and D), suggesting that the
compound heterozygous variants in TRAP1 alone increase cellular
oxidative stress andmight drive autoinflammation in this patient. One
limitation of our results, however, is that we did not look at specific T
lymphocyte subsets. This is of potential importance becuase altered
mtROS production in T lymphocytes might also be a consequence
rather than a cause of the autoinflammatory syndrome (Rashida
Gnanaprakasam et al, 2018).
In the absence of PBMCs from the affected siblings in our in-
formative family, we explored whether defective TRAP1 or pyrin was
the predominant driver of cellular oxidative stress by assessing ROS
levels in THP1 cells differentiated with PMA overnight to a
macrophage-like phenotype, and then transfected with siRNA
targeted against MEFV or TRAP1. On average, these knockdown (kd)
siRNA transfection experiments reduced protein levels for both
gene products by 50%, 48 h posttransfection (Fig S1). Superoxide
(O2−) is highly labile and does not diffuse far before reacting with the
cellular components and generating other free radicals. TRAP1 kd
led to increased levels of superoxide within the mitochondria as
measured by MS fluorescence, although not in the cytoplasm (Fig 2E
and F) compared with scrambled siRNA control cells. MEFV siRNA-
mediated silencing of MEFV resulted in a small increase in cyto-
plasmic superoxide, as measured by DHE fluorescence and had no
significant effect on mitochondrial superoxide levels (Fig 2E and F).
ROS levels have been shown to be increased in FMF patients with
highly penetrant mutations; thus, our finding of slightly increased
cytoplasmic ROS in these MEFV kd experiments could indicate that
cytoplasmic sources such as NADPH oxidases may be important in
FMF (Omenetti et al, 2013). When the rates of O2− production were
compared using electron spin resonance, this was markedly in-
creased in the TRAP1 kd cells but not in the MEFV kd (Fig 2G). This
rate of O2− production was sufficient to induce significant cellular
oxidative stress, detected as an increase in DCF fluorescence after
TRAP1 kd, but not MEFV kd (Fig 2H).
Recessive mutations in TRAP1 have been associated with con-
genital abnormalities of the kidney and urinary tract (CAKUT), and
with vertebral defects, anal atresia, cardiac defects, tracheoesophageal
fistula, renal anomalies, and limb abnormalities (VACTERL) in five
families (Saisawat et al, 2014). These malformation syndromes are
not associated with an autoinflammatory phenotype. Most of these
mutations were in the HSP90 domain of the protein, with each
patient in that report harbouring at least one variant at this lo-
cation; only one patient had a heterozygous variant affecting the
ATP binding domain where the p.R128H TRAP1 variant lies and no
patient was homozygous or compound heterozygous for variants in
this domain. Sequence analysis places the p.R128H variant within
the first α helix of the ATP-binding Bergerat fold in the highly
conserved N-terminal domain (Tanaka et al, 1998; Dutta & Inouye,
2000; Chen et al, 2005). The two additional rare (and predicted
damaging) TRAP1 variants found in patient 4 also affect α helices
and ATPase activity (Table S2). The TRAP1 p.R128H variant was
present in all four of our patients: it was homozygous in the affected
individuals in our informative pedigree and compound heterozy-
gous with the two other variants in the unrelated patient 4. TRAP1
p.R128H is predicted to be damaging by three different in silico
prediction software packages (Polyphen2; SIFT; andMutationTaster)
(Kumar et al, 2009; Adzhubei et al, 2010; Schwarz et al, 2010). Arginine
at position 128 of TRAP1 is conserved throughout the bilateria, when
this protein originated. The N-terminal domain has the highest
sequence conservation across all HSP90 paralogues, and in this
broader family, arginine-128 is conserved throughout the Eukar-
yota. To determine specifically if the TRAP1 p.R128H variant could
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Figure 2. Flow cytometric and electron spin resonance detection of reactive oxygen species.
PBMCs isolated from patient 4 (see main text) and 3 healthy controls (HC) were stained for 15 min with 5 μM MitoSox or 10 μM DHE and analysed immediately by flow
cytometry. Dotted lines in (A, B, C, D) denote HC (one representative experiment); red lines denote patient 4. (A, B) Mitochondrial oxide in monocytes (A) showed no
significant difference, but (B) was increased in lymphocytes from patient 4 (***P < 0.001, two-tailed Z-test). (C, D)Oxidative stress detected by H2DCFDA was elevated in both
patient monocytes (C) and lymphocytes (D). Fig 2E–H: 500,000 THP1 cells were seeded into a 24-well plate with 100 nM PMA. After 24 h, the medium was replaced and
lipofectamine and siRNA complexes were added. After a further 24 h, the medium was replaced with RPMI with 2% FCS for another 24 h. (E, F, G, H) Cells were then
trypsinized and either stained for 15 min with 5 μM MitoSox (E), 10 μM DHE (F), or 10 μM H2DCFDA (H) and analysed immediately by flow cytometry; or the cells were
resuspended in antioxidant buffer, spin probe CMH was then added, and superoxide production was measured 10 times over 10 min via electron spin resonance
spectroscopy (G). Cytoplasmic superoxide was significantly increased in MEFV knockdown (kd) cells compared with scrambled control. Mitochondrial superoxide,
superoxide production, and oxidative stress levels were significantly increased in the TRAP1 kd cells. (I) THP1 cells were transfected with full-length C-terminal DDK-tagged
TRAP1 in a pCMV6-Entry vector, with either wild-type TRAP1 sequence or with the same point mutation inducing the p.R128H protein change or the empty vector alone.
500,000 THP1 cells were seeded into a 24-well plate in RPMI with 10% FCS and 100 nM PMA overnight. Relevant wells were treated with 5 μM CCCP for 6 h. The cells were
then stained with 5 μMMitoSox, trypsinized, and analysed immediately by flow cytometry. At baseline, MitoSox fluorescence was slightly but significantly decreased in only
the WT-TRAP1 overexpressing cells compared with the vector control. Upon treatment with CCCP, mitochondrial superoxide increased in vector control and R128H
mutant TRAP1, but to a significantly lesser extent in the WT-TRAP1 cells. kd, knockdown; WT, wild-type.
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affect superoxide levels, THP1 cells were transfected with full-length
C-terminal DDK-tagged TRAP1 in a pCMV6-Entry vector, with either
wild-type TRAP1 sequence or with the p.R128H point mutation. These
cell lines were then differentiated to a macrophage-like phenotype,
and mitochondrial superoxide levels were measured by flow
cytometry. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is an
ionophore, which uncouples the electron transport chain in the mi-
tochondria, increasing the rate of production of superoxide. Over-
expression of both wild-type and p.R128H mutated TRAP1 protected
the cells from the induction of mROS caused by CCCP, although
significantly less-so for the p.R128H mutant protein, indicating that
this is a hypomorphic mutation that retains some functionality in this
respect (Fig 2I). Overexpression of TRAP1 has been shown to preserve
mitochondrial membrane potential in astrocytes (Voloboueva et al,
2007), and it regulates the opening of the mitochondrial permeability
transition pore (Hua et al, 2007; Xiang et al, 2010), which might explain
this protective effect on membrane potential outside of protein
folding.
As TRAP1 may also have a role in protein folding in the ER, we
evaluated the level of splicing of X-box protein 1 (XBP1) mRNA,
which is increased under conditions of ER stress, in patient 4
compared with three healthy controls. We found that whereas the
amount of unspliced XBP1 (uXBP1) was similar, total amount of spliced
XBP1 (sXBP1) was significantly elevated in patient 4 (P < 0.001), and thus
the ratio of sXBP1/uXBP1 was also increased (P < 0.001) (Fig 3A). sXBP1
is then translated to give the functional transcription factor protein.
The ER and the mitochondria can form tight associations of their
membranes, called mitochondrial associated membranes (MAMs),
which allow exchange of signalling events and molecules between
them. Upon inflammasome activation, NLRP3 and ASC localize to
MAMs, which facilitates detection of ROS production from damaged
mitochondria (Zhou et al, 2011; Missiroli et al, 2018). We also performed
confocal microscopy looking at the cellular localization of TRAP1 in
PBMCs of patient 4 and healthy controls. Interestingly, we found that
TRAP1 mainly resides in the ER of healthy PBMCs at rest, whereas in
patient 4, the organelles show less definition and a greater degree of
association between the mitochondria and the ER and TRAP1 (Fig 3B)
potentially indicating the formation of MAMs.
TRAP1 was so named as it was identified in a yeast 2-hybrid
screen as binding to tumour necrosis factor receptor 1 (TNFR1);
(Song et al, 1995). Given the role of TRAP1 in refolding proteins in
both themitochondria and ER, and that one pathogenicmechanism
in the autoinflammatory disease TRAPS may be accumulation of
structurally misfolded TNFR1 leading to ER stress, XBP1 splicing, and
increased mROS generation (Simon et al, 2010; Bulua et al, 2011;
Dickie et al, 2012), we hypothesized that TRAP1 may chaperone the
folding of TNFR1 in the ER, resulting in increased TRAP1/TNFR1 co-
localization and possible TRAP1 sequestration in patients with
TRAPS. To explore this further, we obtained PBMCs from TRAPS
patients with a range of mutations in TNFRSF1A and determined the
cellular localization of TRAP1 and TNFR1 using confocal microscopy
(Fig 4A). We found a significantly greater degree of co-localization of
these two proteins in patients with structural TNFR1SFA mutations
affecting cysteine, and in a single patient with a TNFRSF1A intron 6
variant (probably also causing major structural protein changes),
compared with patients with milder TNFRSF1A variants (p.R92Q;
p.Y38S; Fig 4B). This suggests a chaperone role for TRAP1 in patients
with TRAPS, potentially regulating mROS production in response to
TNFR1 misfolding. In that context, TNFR1 was measured (by ELISA in
serum as part of routine clinical care) on seven discrete occasions
for IV-1 (and was elevated in 2/7 samples), and on five discrete
occasions in IV-2 (elevated in 3/5 samples). There was no obvious
relationship with other inflammatory markers (Table S3). Regarding
the clinical deterioration in patient IV-1 after a single dose of
infliximab, we noted some similarity with the TRAPS. Infliximab may
provoke increased pro-inflammatory cytokine production in some
patients with TRAPS (Nedjai et al, 2009); the mechanism of clinical
deterioration in IV-1 is, however, unknown.
In addition to the aforementioned serum cytokine studies
performed in IV-1 and IV-2 as part of routine care, we investigated the
levels of a panel of cytokines and chemokines (IL-1, IL-6, IL-8, IL-10,
IL-18, IL-18BP, TNF, INFγ, IP-10, and MCP-1) in the serum of three of
the patients: IV-1, IV-2, and patient 4. We found elevated levels of IL-
18 in all three patients, which normalised in IV-1 and IV-2 to healthy
control levels post-HSCT (Fig 5A). IL-18 is an alarmin, released upon
tissue damage to activate the immune system (Blom & Poulsen,
2012; Chan et al, 2012; Soares et al, 2017). IL-18 binding protein (IL-18-
BP), which is an antagonist of IL-18, was not elevated (Fig 5B). The
levels of the other cytokines tested were within the normal range
(data not shown). IL-1, like IL-18, is produced upon inflammasome
Figure 3. XBP1 splicing and TRAP1 localization.
(A) XBP1mRNA is spliced during the unfolded protein response under ER stress.
XBP1 splicing was evaluated in patient 4 with qPCR and normalised to the average
of three HCs (wild-type WT). There was no significant difference in the level of
unspliced XBP1 (uXBP1), but the amount of spliced XBP1 (sXBP1) was
significantly increased (P < 0.001, two-tailed Z-test) and thus the ratio of sXBP1/
uXBP1 was also increased (P < 0.001, two-tailed Z-test). (B) PBMCs from three HCs
and patient 4 were seeded onto polylysine coverslips and incubated with
mitotracker deep red to label the mitochondria (grey). These were fixed with
methanol and labelled with DAPI (blue), anti-TRAP1 antibodies (green), and anti-
calnexin antibodies (red) to stain the ER. Scale bar = 2 μm. TRAP1 showed
localization to the ER inWT cells. In patient 4, themitochondria showed increased
association with the ER and TRAP1 and less structural definition.
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and caspase-1 activation, but the former is often difficult to detect in
the serum as it acts locally and breaks down quickly. We found that
cultured PBMCs from patient 4 after stimulation produced more IL-18
and IL-1 than healthy control cells (Fig 5C) and showed a greater degree
of caspase-1 activation (Fig 5D) required for the secretion of both these
cytokines. Unfortunately, these experiments were only performed once
because of limited availability of cells.
Anakinra has been shown to partially antagonize IL-18 (Brydges
et al, 2013; Vastert et al, 2014; Standing et al, 2016); the second sister
in the kindred showed partial response, and thus far, patient 4 has
shown complete remission with this treatment, but we cannot
specify if this is due to IL-1, IL-18, or (perhaps more likely) antag-
onism of both these pro-inflammatory cytokines. IL-18 and IL-18-BP
levels, preceding HSCT, in IV-1 and IV-2 were similar to those we
previously reported in patients with the severe autoinflammatory
disease periodic fever immunodeficiency and thrombocytopaenia
(PFIT), caused by recessive mutation in WDR1 (Fig 5A and B)
(Standing et al, 2016). PFIT is also characterised by periodic fevers,
severe oromucosal ulceration, and only partial response to ana-
kinra, ultimately requiring allogeneic HSCT for disease control. We
also previously reported abnormal WDR1 intracellular protein ag-
gregates in PFIT (Standing et al, 2016), which could represent
misfolded protein with propensity to activate IL-18, thus driving
autoinflammation by a similar common pathway as mutated TRAP1.
In summary, we have described a severe autoinflammatory
disease in three siblings associated with homozygousMEFV p.S208C
mutations, and homozygous TRAP1 p.R128H variants characterised
by recurrent fevers, systemic inflammation, oronasal mucosal in-
flammation, transient skin rashes, and noninfectious osteitis with
fatal outcome in one sibling. Allogeneic HSCT was curative in the
two surviving siblings. We suggest that this digenic disease model
might have accounted for the particularly severe phenotype in
this kindred. Discovery of another unrelated patient with auto-
inflammation, with the p.R128H TRAP1 variant in compound het-
erozygous state with two other rare, predicted damaging TRAP1
variants, and our finding that the p.R128H TRAP1 mutation was an
important driver of mROS production supports the suggestion that
bi-allelic hypomorphic TRAP1 mutations might contribute to
autoinflammation. Our findings could, therefore, suggest a role for
TRAP1 as an important protein chaperone, with loss of function
leading to cellular stress and an autoinflammatory phenotype,
driven by IL-18.
Materials and Methods
Ethics
This study was approved by the Bloomsbury ethics committee
(ethics number 08H071382); we obtained written informed consent
from all the family members, patients, and healthy adult controls
who participated. Anonymised paediatric age-matched control
sera, surplus to routine clinical requirements, were obtained from
the Immunology Laboratory at Great Ormond Street Hospital NHS
Figure 4. Confocal microscopy: co-localization of
TRAP1 and TNFR1 in PBMCs from patients with TNF
receptor associated periodic syndrome (TRAPS).
(A) PBMCs were isolated from TRAPS patients with
different mutations and from three HCs (wild-type,
WT), fixed, and labelled with the nuclear stain DAPI
(blue), anti-TNFR1 antibodies (red), and anti-TRAP1
antibodies (green). Scale bar = 5 μm. (B) The degree
of red-green co-localization was quantified in at least
three images for each patient and from three HCs (WT).
*P < 0.05 **P < 0.01 (unpaired two-tailed t tests).
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Foundation Trust and were used in some experiments without
written consent, in accordance with ethical approval for the use of
anonymised laboratory samples surplus to routine requirements.
All study subjects consented to publication of this report, including
clinical images.
Genetic mapping and sequencing
200 ng genomic DNA from patients, siblings, and the parents was
isothermally amplified and enzymatically fragmented before hy-
bridization to Illumina Human610-Quad arrays overnight. These were
imaged using the Illumina iScan. The regions of homozygosity were
identified using Illumina’s Beadstudio with the loss of heterozygosity
detector plug-in (version 1.0.3); the minimum number of contiguous
homozygous single nucleotide polymorphisms was set to 100.
Targeted capture for the whole 5-Mb region (chr16:1079582-5901163,
hg19) was completed using a NimbleGen custom 385k capture array
and sequenced on the Genome Analyzer II (Illumina). The raw
sequence data were aligned to the human reference genome using
the Burrows-Wheeler Aligner alignment algorithm. Variant calling
was with the Genome Analysis ToolKit. Variant annotation was with
ANNOVAR and SNPEFF.
Genetic variants were confirmed and familial segregation ascer-
tained by PCR and Sanger sequencing using the following primers to
amplify and sequence TRAP1 exon 4 forward: 59-TGGGACCCGAGA-
CATCAC-39 and reverse: 59-TGCAGCTGACCAGATAGATCC-39. MEFV exon
2 59-TGTAAAACGACGGCCATAAACGTGGGACAGCTTCATC-39. 59-AGGAAA-
CAGCTATGACCACGTGCCGGCCAGCCATTCTTTCTC-39. Sequencing was com-
pleted with the AB3730 using the BigDye v3.1 kit (Applied Biosystems).
RNA was extracted from control and patient 4 using TRIzol (Invi-
trogen) as per themanufacturer’s instructions and reverse transcribed
with the high-capacity RNA to cDNA kit (Applied Biosystems). TRAP1
transcript was PCR-amplified, using FastStart Taq Polymerase (Roche),
and the following primers: forward 59-CCAGGCCGAGACAAAGAAG-39;
Figure 5. Serum IL-18 measurements.
(A) Serum IL-18 levels in HCs, patient IV-1, and IV-2
before and after haematopoietic stem cell
transplantation and from two patients with the
autoinflammatory disease periodic fever
immunodeficiency and thrombocytopenia (PFIT; see
main text); outlined and grey squares represent
repeated measures from two patients at different
times. Pre-haematopoietic stem cell transplantation
IL-18 levels in IV-1 and IV-2 and patient 4 were
significantly higher than those in HCs and similar to
PFIT patients; ***P < 0.001 (two-tailed unpaired t tests).
(B) Corresponding IL-18 binding protein (IL-18BP) levels
in IV-1, IV-2, and patient 4 which showed no
significant difference to levels in HCs or patients with
PFIT. (C) IL-18 and IL-1 secretion in PBMCs cultured from
patient 4 versus an HC, at baseline or with
stimulation with 100 ng/ml LPS for 4 h, or LPS for 4 h
followed by 5 mM ATP for 15 min. (D) Caspase-1
activation measured as the median fluorescence
intensity of cells stained with FLICA detected by flow
cytometry in patient 4 and an HC. (C, D) Patient shown in
grey and HC in black. Experiment was only performed
once because of limited availability of cells, and thus,
statistical analysis was not possible.
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and reverse 59-GGCCTCATAGTAGGGTGAGTG-39. 4 μl of the resultant PCR
product was annealed with 1 μl pCR2.1-TOPO (Invitrogen). This was
transformed into TOP10 chemically competent Escherichia coli
(Invitrogen) as per the manufacturer’s instructions, grown for 1 h in
Super Optimal broth with Catabolite repression (SOC) broth and
plated onto S-Gal/Luria Broth Agar Blend plates containing 100 μg/ml
ampicillin (Sigma-Aldrich) and grownat 37°C overnight.White colonies
were picked, PCR-amplified with the same primers, and sequenced on
the AB3730 using the BigDye v3.1 kit (Applied Biosystems).
PBMC separation
Blood was collected into Falcon tubes (Thermo Fisher Scientific)
containing 35 U preservative-free heparin (CP Pharmaceuticals) per
50 ml. This was then mixed with equal volumes of Roswell Park
Memorial Institute media (RPMI) and layered onto Lymphoprep
(Axis-Shield). This was centrifuged at 800g for 30 min with the brake
off. The PBMC layer was transferred to a fresh tube and resus-
pended in RPMI and spun at 500g for 10 min.
Confocal microscopy of PBMC
To assess cellular localization of TRAP1 100,000 PBMCs from patient
4, or healthy controls were seeded onto coverslips coated in poly
L-lysine and incubated with 500 nM mitotracker deep red 30 min at
37°C. These were fixed and permeabilized with methanol at −20°C
for 20 min. Subsequently, nonspecific binding was blocked with
donkey serum for 1 h. Coverslips were then incubated with mouse
anti-TRAP1 (BD biosciences) and goat anti-calnexin (Santa-Cruz) at
4°C overnight, followed by Alexa Fluor-488 anti-mouse and Alexa
Fluor-568 anti-goat secondary antibodies for 1 h. Specificity of
TRAP1 antibody staining was confirmed using Western blotting of
wild-type (WT) or TRAP1 kd THP1 cell lysates (data not shown).
To assess TRAP1/TNFR1 co-localization, 100,000 PBMCs from
TRAPS patients or three healthy controls were seeded onto cov-
erslips coated in poly L-lysine and allowed to settle for 45 min.
These were fixed with 4% PFA for 20 min and then permeabilized
with 0.5% triton X for 5 min. After this, nonspecific binding was
blocked with donkey serum for 1 h. Coverslips were then incubated
with mouse anti-TRAP1 (BD biosciences) and rabbit anti-TNFR1
(Santa-Cruz) for 45 min, and subsequently, Alexa Fluor-488 anti-
mouse and Alexa Fluor-568 antirabbit secondary antibodies.
These were mounted with Vectashield mounting medium with
DAPI and imaged using the LSM 710 confocal microscope (ZEISS)
with 63× objective (Plan-Apochromat; numerical aperture, 1.4; working
distance, 190 μm; imaging medium, oil) with Zen2009 software (ZEISS).
Deconvolution was completed using Huygens (Scientific Volume
Imaging B.V.) and co-localization analysis was completed using Imaris
software (Bitplane), and as a percentage of the red (TNFR1) channel
material which co-localized with green (TRAP1). This was compared
with wild-type using the t test.
siRNA transfection
500,000 THP1 cells with 100 nM PMA were seeded per well in a 24-
well plate with 0.5 ml RPMI with 10% FCS without antibiotics. The
following day, the media was changed on the THP1 cells to remove
the PMA. Silencer select predesigned siRNA TRAP1 (s177) and MEFV
(s5660), and scrambled control was obtained from Life Technologies
and resuspended to 50 μM in nuclease-free water. 1 μl of this stock
was diluted in 49 μl of optiMEM (Invitrogen) for each well. 1 μl of
Lipofectamine 2000 (Invitrogen) was diluted in 49 μl of optiMEM per
well. The working solutions of Lipofectamine and RNA were mixed in
equal volumes and incubated for 20 min to permit the formation of
transfection complexes. 100 μl was thenadded to eachwell containing
the cells. The following day, the media was changed to RPMI with 2%
FCS. After a further 24 h, the cells were ready for further experiments.
Overexpression of TRAP1
1 million THP1 cells were transfected with 0.5 μg of pCMV6-AC-DKK
vector (OriGene) containing wild-type or R128H TRAP1, or empty
vector using the Amaxa nucleofector following the manufacturer’s
protocol for kit V. Mutated TRAP1 was produced using Q5-site di-
rected mutagenesis kit (NEB) with the following primers, following
the manufacturer’s instructions. 59-GAAAAACTGCATCACAAACTGGTG-
39 and 59-CAAGGCATCGCTGGCATT-39.
Flow cytometry for ROS detection
Cells were incubated in 10 μM dichlorodihydrofluorescein diacetate
(H2DCFDA), 10 μM dihydrothidium (DHE), or 5 μM MitoSOX (mito-
chondrially targeted DHE) in phenol-free RPMI at 37°C for 30 min.
They were washed and placed on ice and before immediate
analysis by flow cytometry.
Electron spin resonance
Krebs-Hepes buffer was prepared using ultrapure chemicals from
Sigma-Aldrich with iron and copper concentrations below five parts
per million. The Krebs-Hepes buffer was filtered through a 0.22-μM
filter and the pH adjusted to 7.4. Antioxidant buffer was prepared by
adding 25 μMof deferoxamine (DFO) and 5 μMdiethyldithiocarbamate
(DETC). Spin probe solution was made by adding 10 mM of 1-hydroxy-
3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) to antioxi-
dant buffer. Cells to be analysed were trypsinized and resuspended in
45 μl of antioxidant buffer on ice. Immediately before analysis, 2.5 μl of
spin probe solution was added, the cells were drawn into the capillary
tube, and placed in the E-SCANholder in the temperature controller at
37°C. The samples were analysed using the E-SCAN using the settings
in Table 1.
XBP1 splicing qPCR
For XBP1 splicing analysis, PBMC cDNA from patient 4 and three
healthy controls was measured using quantitative PCR with the
standard curve method. qPCR was performed with the RotorGene
6000 machine (Corbett) and SYBR green JumpStart Taq ReadyMix
(Sigma-Aldrich) following the manufacturers recommendations and
using the following primers. Spliced XBP1 forward: 59-CTGAGTCCG-
CAGCAGGTG-39, unspliced XBP1 forward: 59-TCCGCAGCACTCAGACTACG-
39 and XBP1 reverse: 59-AGTTGTCCAGAATGCCCAACA-39 . HPRT
housekeeping control forward: 59-GGAAAGAATGTCTTGATTGTGGAAG-39
and reverse: 59-GGATTATACTGCCTGACCAAGGAA-39.
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Measurement of cytokines
IL-18 was measured using a Meso Scale Discovery multiplex kit
(Meso Scale Diagnostics), as per the manufacturer’s instructions in
patients and control sera. Control sera was obtained from healthy
paediatric controls obtained for the development of diagnostic
tests for primary immunodeficiency (Research Ethics Committee
reference 06/Q0508/16; n = 40; 18 males; median age, 5 yr; range,
0.3–17 yr).
Statistical analyses
Unpaired t tests and graphs were produced using Prism version 4
(GraphPad). Z-tests were completed in excel. P < 0.05 was con-
sidered significant.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900376.
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